Listen to this story

Subscriber Benefit As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now This audio file is brought to you by

0:00 0:00 Loading audio file, please wait. Speed

1.00

0.25

0.50

0.75

1.00

1.25

1.50

1.75

2.00

Eli Lilly and Co. shares dropped more than 14% after the company released its second-quarter financial results and what some analysts see as “disappointing” data regarding the latest trials of its weight-loss pill.

The Indianapolis-based pharmaceutical giant beat analysts’ expectations across the board, reporting revenue of $15.6 billion for the second quarter, up 38% compared to the same period a year ago.

Reported earnings per share was more than $6, above the $5.61 per share expected by analysts,

See Full Page